Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Leriglitazone
1. 146062-44-4
2. Leriglitazone
3. Hydroxy Pioglitazone (m-iv)
4. Min-102
5. Chebi:82937
6. Leriglitazone [usan]
7. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
8. K824x25aya
9. 2,4-thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-
10. 2,4-thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-
11. Hydroxy Pioglitazone-d4 (m-iv) (deuterated)
12. Hydroxy Pioglitazone
13. 1-hydroxypioglitazone
14. Pioglitazone, Hydroxy
15. Leriglitazone [inn]
16. Leriglitazone (usan/inn)
17. Chembl1267
18. Unii-k824x25aya
19. Schembl4098326
20. Dtxsid30399914
21. Bdbm50530214
22. Who 10868
23. Zinc01482947
24. Akos015856344
25. Db15021
26. 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione
27. Hydroxy Pioglitazone (m-iv Metabolite)
28. Db-042820
29. Hy-117727
30. Cs-0067030
31. Ft-0643388
32. D11603
33. 062h444
34. U-91322
35. A1-01710
36. J-008187
37. Q27156475
38. 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione
39. 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
40. 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione
41. All-ambo-5-((4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)phenyl)methyl)-1,3-thiazole-2,4(3h,5h)-dione
| Molecular Weight | 372.4 g/mol |
|---|---|
| Molecular Formula | C19H20N2O4S |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 372.11437830 g/mol |
| Monoisotopic Mass | 372.11437830 g/mol |
| Topological Polar Surface Area | 114 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 496 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of adrenoleukodystrophy
5-[(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione is a known human metabolite of Pioglitazone.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Leriglitazone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Leriglitazone, including repackagers and relabelers. The FDA regulates Leriglitazone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Leriglitazone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Leriglitazone supplier is an individual or a company that provides Leriglitazone active pharmaceutical ingredient (API) or Leriglitazone finished formulations upon request. The Leriglitazone suppliers may include Leriglitazone API manufacturers, exporters, distributors and traders.
Leriglitazone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Leriglitazone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Leriglitazone GMP manufacturer or Leriglitazone GMP API supplier for your needs.
A Leriglitazone CoA (Certificate of Analysis) is a formal document that attests to Leriglitazone's compliance with Leriglitazone specifications and serves as a tool for batch-level quality control.
Leriglitazone CoA mostly includes findings from lab analyses of a specific batch. For each Leriglitazone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Leriglitazone may be tested according to a variety of international standards, such as European Pharmacopoeia (Leriglitazone EP), Leriglitazone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Leriglitazone USP).
LOOKING FOR A SUPPLIER?
